[go: up one dir, main page]

HK1229709A1 - Combination therapy for treating cancer - Google Patents

Combination therapy for treating cancer

Info

Publication number
HK1229709A1
HK1229709A1 HK17103439.4A HK17103439A HK1229709A1 HK 1229709 A1 HK1229709 A1 HK 1229709A1 HK 17103439 A HK17103439 A HK 17103439A HK 1229709 A1 HK1229709 A1 HK 1229709A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
treating cancer
cancer
prednisone
subjects
Prior art date
Application number
HK17103439.4A
Other languages
Chinese (zh)
Other versions
HK1229709B (en
Inventor
Keilhack Heike
K. Knutson Sarah
W. Kuntz Kevin
Original Assignee
Epizyme, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme, Inc. filed Critical Epizyme, Inc.
Publication of HK1229709A1 publication Critical patent/HK1229709A1/en
Publication of HK1229709B publication Critical patent/HK1229709B/en

Links

Abstract

The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
HK17103439.4A 2013-12-06 2014-12-08 Combination therapy for treating cancer HK1229709B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361913063P 2013-12-06
US201461934388P 2014-01-31
US201461992881P 2014-05-13

Publications (2)

Publication Number Publication Date
HK1229709A1 true HK1229709A1 (en) 2017-11-24
HK1229709B HK1229709B (en) 2021-12-10

Family

ID=

Similar Documents

Publication Publication Date Title
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
EP4140487A8 (en) Combination therapy for treating cancer
MX2016007351A (en) COMBINATION THERAPY TO TREAT CANCER.
WO2016025635A3 (en) Combination therapy for treating cancer
SG10201902664RA (en) Combination therapy for treating cancer
WO2016043874A3 (en) Combination therapy for treating cancer
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
MX2020010535A (en) Methods of treating cancer.
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
WO2015009726A3 (en) Medical uses of cd38 agonists
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2018002344A (en) Method for treating cancer.
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
MX2015010791A (en) Methods of treating cancer and preventing drug resistance.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12016501527A1 (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
HK1259026A1 (en) Localized delivery of anti-fugetactic agent for treatment of cancer
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.